Source comparison
Pulsatile Versus Continuous Dosing Protocols
Endogenous GnRH is secreted in pulses every 60–120 minutes. Continuous GnRH receptor stimulation paradoxically downregulates gonadotropin release, the mechanism exploited by GnRH agonist therapies for prostate cancer and endometriosis. Kisspeptin research must
This comparison does not assign a generated winner or score.
- Endogenous GnRH is secreted in pulses every 60–120 minutes. Continuous GnRH receptor stimulation paradoxically downregulates gonadotropin release, the mechanism exploited by GnRH agonist therapies for prostate cancer and endometriosis. Kisspeptin research must account for this: continuous IV infusion at 1.0mcg/kg/hour initially elevates LH but causes receptor desensitisation within 4–6 hours, blunting testosterone response.
- Pulsatile kisspeptin administration better mimics natural HPG axis function. A 2025 study in Endocrinology administered kisspeptin-54 as 1.0mcg/kg IV boluses every 90 minutes over 12 hours versus continuous infusion at equivalent total dose. The pulsatile group maintained LH levels 40–60% above baseline throughout the protocol, while the continuous group showed LH suppression below baseline by hour 8. Testosterone levels followed the same pattern: pulsatile dosing sustained a 25% increase from baseline, continuous dosing returned to baseline by hour 6.
- For practical research design: if the objective is acute LH response measurement, a single bolus suffices. If modelling multi-day testosterone dynamics, intermittent dosing (once or twice daily) prevents receptor downregulation. Daily subcutaneous kisspeptin-54 at 2.0–3.0mcg/kg maintains elevated testosterone without tachyphylaxis for up to 7 days in published protocols, though individual variability in receptor density means some models show blunted response by day 5.